Masuda Takaaki, Hayashi Naoki, Iguchi Tomohiro, Ito Shuhei, Eguchi Hidetoshi, Mimori Koshi
Kyushu University Beppu Hospital, Department of Surgery, Japan.
Kyushu University Beppu Hospital, Department of Surgery, Japan.
Mol Oncol. 2016 Mar;10(3):408-17. doi: 10.1016/j.molonc.2016.01.010. Epub 2016 Feb 10.
During the process of metastasis, which is the leading cause of cancer-related death, cancer cells dissociate from primary tumors, migrate to distal sites, and finally colonize, eventually leading to the formation of metastatic tumors. The migrating tumor cells in circulation, e.g., those found in peripheral blood (PB) or bone marrow (BM), are called circulating tumor cells (CTCs). CTCs in the BM are generally called disseminated tumor cells (DTCs). Many studies have reported the detection and characterization of CTCs to facilitate early diagnosis of relapse or metastasis and improve early detection and appropriate treatment decisions. Initially, epithelial markers, such as EpCAM and cytokeratins (CKs), identified using immunocytochemistry or reverse transcription polymerase chain reaction (RT-PCR) were used to identify CTCs in PB or BM. Recently, however, other markers such as human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and immuno-checkpoint genes also have been examined to facilitate detection of CTCs with metastatic potential. Moreover, the epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) have also received increasing attention as important CTC markers owing to their roles in the biological progression of metastasis. In addition to these markers, researchers have attempted to develop detection or capture techniques for CTCs. Notably, however, the establishment of metastasis requires cancer-host interactions. Markers from host cells, such as macrophages, mesenchymal stem cells, and bone marrow-derived cells, which constitute the premetastatic niche, may become novel biomarkers for predicting relapse or metastasis or monitoring the effects of treatment. Biological studies of CTCs are still emerging. However, recent technical innovations, such as next-generation sequencing, are being used more commonly and could help to clarify the mechanism of metastasis. Additionally, biological findings are gradually being accumulated, adding to our body of knowledge on CTCs. In this review, we will summarize recent approaches to detect or capture CTCs. Moreover, we will introduce recent studies of the clinical and biological importance of CTCs and host cells.
在转移过程中,转移是癌症相关死亡的主要原因,癌细胞从原发性肿瘤脱离,迁移到远处部位,最终定植,最终导致转移性肿瘤的形成。循环中的迁移肿瘤细胞,例如在外周血(PB)或骨髓(BM)中发现的那些细胞,被称为循环肿瘤细胞(CTC)。BM中的CTC通常被称为播散肿瘤细胞(DTC)。许多研究报告了CTC的检测和特征分析,以促进复发或转移的早期诊断,并改善早期检测和适当的治疗决策。最初,使用免疫细胞化学或逆转录聚合酶链反应(RT-PCR)鉴定的上皮标志物,如上皮细胞粘附分子(EpCAM)和细胞角蛋白(CKs),被用于鉴定PB或BM中的CTC。然而,最近,其他标志物,如人表皮生长因子受体2(HER2)、雌激素受体(ER)和免疫检查点基因,也已被研究,以促进具有转移潜能的CTC的检测。此外,上皮-间质转化(EMT)和癌症干细胞(CSC)也因其在转移生物学进展中的作用,作为重要的CTC标志物而受到越来越多的关注。除了这些标志物外,研究人员还尝试开发CTC的检测或捕获技术。然而,值得注意的是,转移的建立需要癌症与宿主的相互作用。构成转移前生态位的宿主细胞标志物,如巨噬细胞、间充质干细胞和骨髓来源的细胞,可能成为预测复发或转移或监测治疗效果的新型生物标志物。CTC的生物学研究仍在不断涌现。然而,最近的技术创新,如下一代测序,正在更广泛地使用,并有助于阐明转移机制。此外,生物学研究结果也在逐渐积累,增加了我们对CTC的认识。在这篇综述中,我们将总结最近检测或捕获CTC的方法。此外,我们还将介绍最近关于CTC和宿主细胞的临床和生物学重要性的研究。